Drawing for LIDOSPOT

USPTO serial 86959351

LIDOSPOT

Reviewed by CopyMark Law Group

Reg. 5090079Status 702Renewal
Filing date
Status date
Registration date
Nov 29, 2016
Examiner
HISER, CHARLES
Law office
TMO LAW OFFICE 112

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with LIDOSPOT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roger J. Bernstein

551 Fifth Ave., 12th FlNEW YORK, NY 10176UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Bandages impregnated with adhesive and Lidocaine; Dermatological pharmaceutical products; Drug delivery agents in the form of a coating for bandages and patches that facilitate the delivery of a wide range of pharmaceuticals; Pharmaceutical agents for epidermis; Transdermal patches featuring anesthetic, namely, LidocaineACTIVEMar 1, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 29, 2025REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Oct 17, 2022NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Oct 17, 2022C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 12, 2022EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Jun 3, 2022PR23POST REGISTRATION ACTION MAILED - SEC. 8 & 15—
Jun 3, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 27, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 27, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 27, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 12, 2021E815TEAS SECTION 8 & 15 RECEIVED—
Nov 29, 2021REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 29, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 13, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 13, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 24, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 5, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 29, 2016ALIEASSIGNED TO LIE—
Jul 20, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 20, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Jul 20, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 20, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 20, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 14, 2016DOCKASSIGNED TO EXAMINER—
Apr 6, 2016MPMKNOTICE OF PSEUDO MARK E-MAILED—
Apr 5, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 4, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance